Cutaneous melanoma – guidelines for diagnostics and therapy in 2016

Rutkowski, Piotr; Wysocki, Piotr J.; Nasierowska‐Guttmejer, Anna; Fijuth, Jacek; Kalinka, Ewa; Świtaj, Tomasz; Jeziorski, Arkadiusz; Szacht, Milena; Zegarski, Wojciech; Wysocki, Wojciech M.; Rudnicka, Lidia; Owczarek, Witold; Krzakowski, Maciej

doi:10.5114/dr.2016.57736

Cited by 13 publications

(25 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The several algorithms for analyzing the dermoscopic views are available. The rudimentary one -3-point scale -enables the physician to make the diagnosis of MM with 96,3% of sensitivity and 94,2% of specificity (1). The routine dermoscopy of melanocytic lesions should be performed every 3 years in patients under the age of 40 and every year thereafter.…”

Section: Diagnosis and Managementmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous and mucosal melanoma

Sobolewski

Dopytalska

Roszkiewicz

et al. 2019

View full text Add to dashboard Cite

Malignant melanoma (MM) still remains a potentially fatal disease despite the fact that advanced diagnostic methods and modern therapeutic options are available. Melanoma is a cancer deriving from neuroectodermal melanocytic cells. The standardized incidence rate of melanoma in Poland is 4,9 per 100 000. The mucosal melanoma is a rare form of this cancer accounting for only 2% of the diagnosed cases. The fast diagnosis and surgical treatment are the keys to decreased mortality. In metastatic disease systemic therapy is needed but no highly efficient drug has been identified yet. This paper concentrates on introduction of elemental knowledge about melanoma to raise awareness among medical professionals of different specialities in order not to overlook any case of melanoma.

show abstract

Section: Diagnosis and Managementmentioning

confidence: 99%

“…Molecularly targeted treatment of melanoma (BRAF and MEK inhibitors) is nowadays available and the median survival period in individual cases can be extended to 20-25 months. Nevertheless, further studies are needed (1).…”

Section: Diagnosis and Managementmentioning

confidence: 99%

Cutaneous and mucosal melanoma

Sobolewski

Dopytalska

Roszkiewicz

et al. 2019

View full text Add to dashboard Cite

show abstract

“…This percentage increased significantly in recent years mainly due to the wide introduction of imaging techniques. In 2011 in Poland kidney cancer was diagnosed in more than 2,700 men and 1,800 women and died from the disease 1500 men and 1000 women [1]. Men dominate among patients (1,5 : 1) [2].…”

Section: Introductionmentioning

confidence: 99%

“…The etiology of sporadic cases is not known, however cigarette smoking, obesity and dialysis are associated with higher incidence of the disease [1]. …”

Section: Introductionmentioning

confidence: 99%

Axitinib in metastatic renal cell carcinoma: single center experience

Buraczewska

Kardas

2016

View full text Add to dashboard Cite

Aim of the studyDue to the emergence of new therapeutic opportunities in the second-line treatment of metastatic renal cell carcinoma, the choice of the appropriate medication requires consideration. Making the selection one should take into account the likelihood of response, the probability of toxicity, properties of the drug and the clinical characteristics of the patient. Aim of the work was to confirm antitumor efficacy of axitinib in patients with metastatic clear-cell renal-cell carcinoma in the second line treatment remaining under the care of our institution. The primary objective was to determine antitumor activity, secondary – to evaluate progression free survival, safety of the treatment and to analyse clinical characteristics of treated population.ResultsTreatment records of 27 patients (9 females, 18 males) treated from October 2014 to the present (July 2016) were reviewed. The median duration of treatment which corresponds to the time to disease progression in observed population was 6 months (range: under 1 month – 16 months). 1 patient (3.7%) had got objective response (PR, partial remission). Clinical benefit rate (PR + SD (stable disease) was 66%. 9 patients (33.33%) experienced treatment toxicity only in the first degree of CTCAE (common toxicity criteria for adverse events), 11 patients (40.74%) presented the second degree toxicity and 5 patients (18.5%) – third degree. The most commonly reported treatment related adverse events were diarrhea (47%), fatigue (26%), hand-foot syndrome (26%), deterioration of blood pressure control (22.2%), abnormal liver function tests (18.5%), mucositis (11.1%). We observed 3 cases of unacceptable toxicity.ConclusionsAxitinib confirms its effectiveness also in situation outside clinical trials, however, it is characterized by significant toxicity. Therefore, qualification for treatment should take into account the clinical patient characteristics. Effective diagnosis and treatment of side effects and dose optimization are the key skills of the attending physician.

show abstract

“…According to Polish and American recommendations (NCCN, ASCO/SSO) [4][5][6], radical lymphadenectomy should be considered after histopathological examination of melanoma metastases in the node or sentinel nodes (especially at micro-metastases > 1 mm or when the risk of metastases to other nodes is higher). This is important because in other lymph nodes (non-sentinel lymph node -NSLN) melanoma metastases are found by routine histopathological methods in about 20-30% of patients [7].…”

mentioning

confidence: 99%

Cutaneous melanoma – guidelines for diagnostics and therapy in 2016

Cited by 13 publications

References 28 publications

Cutaneous and mucosal melanoma

Cutaneous and mucosal melanoma

Axitinib in metastatic renal cell carcinoma: single center experience

Should a completion lymphadenectomy be performed after a positive biopsy of the sentinel node in melanoma? A vote for „yes”

Contact Info

Product

Resources

About